ホームATHA • NASDAQ
add
Athira Pharma Inc
前日の終値
$0.56
日次変動幅
$0.50 - $0.55
年間変動幅
$0.41 - $4.30
時価総額
2002.42万 USD
平均取引高
24.58万
株価収益率
-
配当利回り
-
優先市場
NASDAQ
市場ニュース
財務情報
損益計算書
収益
純利益
(USD) | 2024年9月info | 前年比変化率 |
---|---|---|
収益 | — | — |
営業費用 | 2549.40万 | -27.25% |
純利益 | -2874.10万 | 12.83% |
純利益率 | — | — |
1 株当たりの収益 | — | — |
EBITDA | -2525.10万 | 27.44% |
実効税率 | — | — |
貸借対照表
総資産
負債総額
(USD) | 2024年9月info | 前年比変化率 |
---|---|---|
現金および短期投資 | 6885.60万 | -60.19% |
総資産 | 8624.60万 | -53.30% |
負債総額 | 2866.30万 | -4.25% |
純資産 | 5758.30万 | — |
発行済み株式 | 3866.91万 | — |
帳簿価格 | 0.37 | — |
総資産利益率 | -64.54% | — |
資本利益率 | -88.74% | — |
キャッシュ フロー
現金の純増減額
(USD) | 2024年9月info | 前年比変化率 |
---|---|---|
純利益 | -2874.10万 | 12.83% |
営業キャッシュ フロー | -2302.30万 | 4.01% |
投資キャッシュ フロー | 1803.90万 | -12.81% |
財務キャッシュ フロー | 1.20万 | — |
現金の純増減額 | -497.20万 | -50.94% |
フリー キャッシュ フロー | -1012.78万 | 13.86% |
概要
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
設立
2011
本社所在地
ウェブサイト
従業員数
66